Clinical Trials Logo

Clinical Trial Summary

This study will test whether seven days administration of a serotonin receptor subtype 4 (5HT4) agonist called PF-04995274 has positive effects on emotional processing and neural activity in unmedicated depressed patients compared to placebo. The study will also include a group of patients randomised to seven days administration of citalopram (20 mg), which is a standard treatment for depression.


Clinical Trial Description

This study uses a double-blind, placebo-controlled, randomised between-groups design to test if administration of a serotonin receptor subtype 4 (5HT4) agonist called PF-04995274 has positive effects on emotional processing and neural activity in unmedicated depressed patients. Participants are patients who fulfill criteria for current episode of Major Depressive Disorder (MDD), and they will be randomised to receive 7 days treatment with either PF-04995274 (15 mg daily), citalopram (20 mg daily) or a matched placebo. Participants will come for a Screening Visit, a First Dose Visit, Research Visit One (including MRI scan) and Research Visit Two (including measures of emotional processing and non-emotion cognition). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03516604
Study type Interventional
Source University of Oxford
Contact Amy Gillespie
Phone 01865 618324
Email amy.gillespie@psych.ox.ac.uk
Status Recruiting
Phase Phase 1
Start date May 16, 2018
Completion date April 30, 2020

See also
  Status Clinical Trial Phase
Completed NCT03556735 - Pulsed Electro Magnetic Fields (PEMF) in Depression N/A
Recruiting NCT02945735 - Gaze Contingent Feedback in Major Depressive Disorder (MDD) N/A
Recruiting NCT03537547 - Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder Phase 4
Recruiting NCT03515733 - PF-04995274 and Emotional Processing in Treatment Resistant Depression Phase 1
Recruiting NCT03538275 - Medibio Depression Monitoring Study
Recruiting NCT03096886 - Novel Neural Circuit Biomarkers of Depression Response to CCBT N/A
Not yet recruiting NCT03466346 - Depression And Primary-care Partnership for Effectiveness-implementation Research N/A
Completed NCT01874951 - Low-Dose Naltrexone for Depression Relapse and Recurrence Phase 2
Completed NCT02874833 - Exercise for Depression N/A
Recruiting NCT03405493 - Sleep, Wake and Light Therapy for Depression N/A
Recruiting NCT03246789 - Reaching and Engaging Depressed Senior Center Clients (REDS) N/A
Enrolling by invitation NCT02954731 - Trans-diagnostic Group CBT vs. Standard Group CBT for Depression, Social Anxiety and Agoraphobia/Panic Disorder N/A
Recruiting NCT02969876 - Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine Phase 4
Recruiting NCT03623711 - A Prediction Study of Multiple Indexes of the Effect of Different Mechanisms of Antidepressants Treatment on Depression Early Phase 1
Recruiting NCT03169543 - Neural Mechanisms Underlying the Antidepressant Effects of Sleep Deprivation N/A